Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

A nasal spray that was distributed across the United States has been recalled due to its potential to cause 'life-threatening ...

She considers herself lucky. She happened to find a doctor who immediately did a biopsy and sent her sample to a lab that likely didn’t have much else to investigate during the pandemic. Whoever her ...

Cystic fibrosis, a genetic disorder, affects lungs and other organs. It causes thick mucus buildup. Researchers have ...

GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines ...

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a ...

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...